Expression and prognostic value of the transcription factors EGR1 and EGR3 in gliomas

Scientific Reports
Arnon Møldrup KnudsenBjarne Winther Kristensen

Abstract

Most glioblastoma patients have a dismal prognosis, although some survive several years. However, only few biomarkers are available to predict the disease course. EGR1 and EGR3 have been linked to glioblastoma stemness and tumour progression, and this study aimed to investigate their spatial expression and prognostic value in gliomas. Overall 207 gliomas including 190 glioblastomas were EGR1/EGR3 immunostained and quantified. A cohort of 21 glioblastomas with high P53 expression and available tissue from core and periphery was stained with double-immunofluorescence (P53-EGR1 and P53-EGR3) and quantified.EGR1 expression increased with WHO-grade, and declined by 18.9% in the tumour periphery vs. core (P = 0.01), while EGR3 expression increased by 13.8% in the periphery vs. core (P = 0.04). In patients with high EGR1 expression, 83% had methylated MGMT-promoters, while all patients with low EGR1 expression had un-methylated MGMT-promoters. High EGR3 expression in MGMT-methylated patients was associated with poor survival (HR = 1.98; 95%CI 1.22-3.22; P = 0.006), while EGR1 high/EGR3 high, was associated with poor survival vs. EGR1 high/EGR3 low (HR = 2.11; 95%CI 1.25-3.56; P = 0.005). EGR1 did not show prognostic value, but could b...Continue Reading

Citations

May 18, 1999·The Journal of Biological Chemistry·S F YanD M Stern
Jan 9, 2004·Cancer Cell International·A CalogeroG Ragona
Jan 31, 2004·Annals of the New York Academy of Sciences·V BaronD Mercola
Dec 17, 2009·Cancer Biology & Therapy·J Thomas DeLigio, Diego A R Zorio
Mar 6, 2013·Journal of Molecular Histology·Fei LiaoWei-guo Dong
Apr 24, 2013·Archives of Medical Research·Yang ChenYing Zhang
Nov 7, 2013·JAMA : the Journal of the American Medical Association·Antonio Omuro, Lisa M DeAngelis
Jan 30, 2014·PloS One·Rose M ParkinsonJonathan D Powell
May 7, 2015·Neuropathology and Applied Neurobiology·Sebastian Brandner, Andreas von Deimling
Jan 15, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Damir VareslijaLeonie Young
Mar 24, 2016·The Journal of Biological Chemistry·Nathalie SakakiniThierry Virolle
Aug 12, 2016·Journal of Neuro-oncology·Sune MuntheBjarne Winther Kristensen
Nov 20, 2016·Rheumatology·Kaoru MoritaKazuhiko Yamamoto
Dec 23, 2016·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·S S KumarJ E Hardingham
Dec 30, 2016·Neuro-oncology·Robert L BowmanMassimo Squatrito
Jan 11, 2017·Journal of Zhejiang University. Science. B·Zhong-Dong WangHai-Dong Zhang
Mar 8, 2017·Journal of Cellular Physiology·Maryam Moradi BinabajAmir Avan
Sep 2, 2017·Central-European Journal of Immunology·Sina TaefehshokrAmin Oveisi
May 12, 2018·Science·Ralph B PuchalskiGreg D Foltz

Related Concepts

EGR3 protein, human
Promoter
Glioblastoma
Staining Method
EGR3
Peripheral
Cohort
Protein p53
EGR3 gene
O(6)-Methylguanine-DNA Methyltransferase

Related Feeds

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.